Figure 1From: Abiraterone acetate in patients with metastatic castration-resistant prostate cancer: long term outcome of the Temporary Authorization for Use programme in FranceOverall survival from the beginning of Abiraterone Acetate for the three categories of patients (treatment duration ≤3 months, [3,6], >6 months). (A) 3 months Landmark analysis. (B) 6 months Landmark analysis.Back to article page